Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

IMGN

ImmunoGen (IMGN)

ImmunoGen Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:IMGN

1 2 3 4 5 6 7 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
22/02/2024	22h15	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:IMGN	ImmunoGen Inc
14/02/2024	23h01	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:IMGN	ImmunoGen Inc
12/02/2024	22h48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMGN	ImmunoGen Inc
12/02/2024	22h33	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:IMGN	ImmunoGen Inc
12/02/2024	15h32	Edgar (US Regulatory)	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:IMGN	ImmunoGen Inc
12/02/2024	13h52	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMGN	ImmunoGen Inc
12/02/2024	13h37	PR Newswire (US)	AbbVie Completes Acquisition of ImmunoGen	NASDAQ:IMGN	ImmunoGen Inc
05/02/2024	22h10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMGN	ImmunoGen Inc
01/02/2024	22h30	Business Wire	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:IMGN	ImmunoGen Inc
29/01/2024	23h01	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:IMGN	ImmunoGen Inc
12/01/2024	17h10	PR Newswire (US)	Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law Firm	NASDAQ:IMGN	ImmunoGen Inc
03/01/2024	00h10	PR Newswire (US)	Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law Firm	NASDAQ:IMGN	ImmunoGen Inc
02/01/2024	22h26	Edgar (US Regulatory)	Form DEFM14A - Definitive proxy statement relating to merger or acquisition	NASDAQ:IMGN	ImmunoGen Inc
21/12/2023	22h52	Edgar (US Regulatory)	Form PREM14A - Preliminary proxy statements relating to merger or acquisition	NASDAQ:IMGN	ImmunoGen Inc
20/12/2023	01h00	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:IMGN	ImmunoGen Inc
10/12/2023	18h00	Business Wire	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	NASDAQ:IMGN	ImmunoGen Inc
08/12/2023	12h23	IH Market News	Apple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest Updates	NASDAQ:IMGN	ImmunoGen Inc
05/12/2023	13h46	Dow Jones News	Immunogen Gets FDA Priority Review of Elahere Full Approval	NASDAQ:IMGN	ImmunoGen Inc
30/11/2023	14h42	Dow Jones News	ImmunoGen Shares Soar Premarket on Takeover by AbbVie	NASDAQ:IMGN	ImmunoGen Inc
30/11/2023	14h13	Dow Jones News	AbbVie to Buy ImmunoGen for More Than $10 Billion	NASDAQ:IMGN	ImmunoGen Inc
30/11/2023	13h30	PR Newswire (US)	AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio	NASDAQ:IMGN	ImmunoGen Inc
02/11/2023	21h30	Business Wire	ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference	NASDAQ:IMGN	ImmunoGen Inc
02/11/2023	21h05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMGN	ImmunoGen Inc
02/11/2023	11h30	Business Wire	ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results	NASDAQ:IMGN	ImmunoGen Inc
27/10/2023	12h30	Business Wire	ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer	NASDAQ:IMGN	ImmunoGen Inc
23/10/2023	14h30	PR Newswire (US)	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board	NASDAQ:IMGN	ImmunoGen Inc
19/10/2023	22h01	Business Wire	ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results	NASDAQ:IMGN	ImmunoGen Inc
28/09/2023	13h00	Business Wire	ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer	NASDAQ:IMGN	ImmunoGen Inc
19/09/2023	23h37	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IMGN	ImmunoGen Inc
18/09/2023	12h30	Business Wire	ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer	NASDAQ:IMGN	ImmunoGen Inc

Showing the most relevant articles for your search:NASDAQ:IMGN

1 2 3 4 5 6 7 Suivant >>

JP Morgan Chase

Societe Generale

Cie de SaintGobain

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales